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Editorial
Aortic Regurgitation After Transcatheter  
Aortic Valve Replacement: Is it a Fall from  
Grace or Just a Storm in a Teacup?
Marco A. Magalhães1, Ron Waksman2, Augusto D. Pichard3
A decade of great enthusiasm has emerged after the first-in-man, successful transcatheter aortic valve replacement (TAVR) report in 2002. Sub-
sequently, the results of the pivotal randomized Place-
ment of AoRTic TraNscathetER (PARTNER) trial were 
instrumental for the TAVR approval as the standard of 
care for symptomatic inoperable aortic stenosis.1 This 
10-year successful history had major drawbacks that 
were mostly related to the procedure and overcome, 
in part, by technique and device refinements. Although 
the short-term outcomes have improved (< 10%), the 
long-term mortality post-TAVR has not changed over 
time.2-5 Moreover, the high incidence and the association 
of post-TAVR aortic regurgitation with mortality have 
been raising concerns.6,7 However important method-
ological considerations across these studies hamper the 
understanding of whether this phenomenon represents 
a “fall from grace” or just a “storm in a teacup”.
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The reported incidence of aortic regurgitation post- 
TAVR ranges from 50% to 85% and derives mostly from 
echocardiographic data.8 The aortic regurgitation can be 
either central or paravalvular (leak) in origin and graded 
according to quantitative or semi-quantitative parameters. 
But none of these methods were prospectively validated 
nor consensually standardized by the Valve Academic 
Research Consortium.9 Ack nowledging these limita-
tions, apparently more than mild aortic regurgitation 
post-TAVR has been associated with worse long-term 
outcomes in different studies with a pooled hazard 
ratio of 2.27 [95% confidence interval (95%CI): 1.84-
2.81] at 1 year.7 Nonetheless, the most intriguing data 
came from PARTNER trial (Cohort A) where even mild 
aortic regurgitation post-TAVR was related to a higher 
mortality and a real gradient effect was demonstrated.6
The manuscript published by Lluberas et al.10 in 
this issue of Revista Brasileira de Cardiologia Invasiva 
adds important post-TAVR paravalvular aortic regurgita-
tion data based upon a retrospective analysis of 112 
(68.8%) symptomatic aortic stenosis patients treated with 
Medtronic CoreValve (Medtronic, Minneapolis, USA) 
device, mostly at a single pioneer center in Brazil. The 
authors reported a frequency of 56% of post-procedural 
paravalvular aortic regurgitation. Of these, 41% were 
mild and 11.6% moderate. No severe paravalvular aortic 
regurgitation was noted. This incidence is similar to the 
literature but in the lower range for the CoreValve 
studies (9% to 21%).11 The incidence of moderate or 
severe paravalvular aortic regurgitation interesting finding 
may be related to a more liberal use of balloon post-
dilatation (34%). Although underpowered for clinical 
end-points, no mortality difference was observed at 
one-year follow-up comparing the moderate paravalvular 
aortic regurgitation to mild or no aortic regurgitation 
(7.7% vs. 8.1%, respectively; P = NS).
This finding highlights the conflicting evidence sur-
rounding the post-TAVR aortic regurgitation mortality 
association. Numerous studies have shown the associa-
tion of aortic regurgitation post-TAVR and mortality but 
important analytical and methodological considerations 
such as the proportional hazard function, the survivor-
ship bias, the lack of standardized definition criteria, 
the timing and inherent limitations of echocardiographic 
evaluation and the limited data provided by indepen-
dent echo core lab diminish the strength of this asso-
ciation. All together, these considerations mitigate the 
establishment of a direct causal relationship. In other 
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words, the link between post-TAVR aortic regurgitation 
and mortality can be mediated or moderated by either 
measured or unmeasured confounders and thus is far 
from being closed. In this arguing line, Lluberas et al.10 
provide a further insight into the theme by modeling 
the baseline determinants of paravalvular aortic regur-
gitation post-TAVR. But, the limited event number (n = 
13) most likely over-fitted the model and the estimates. 
Interestingly, the only independent echocardiographic 
baseline predictor was the presence of left ventricular 
ejection fraction < 35% [odds ratio (OR): 4.16, CI: 1.01-
17.0; P = 0.048] which is comparable to the core lab 
based longitudinal study from PARTNER trial pointing 
out for a baseline ventricular remodeling difference in 
patients who develop post-TAVR aortic regurgitation.12 
Moreover, this study has documented that the post-TAVR 
aortic regurgitation remains mostly unchanged during 
the 2 years fol low-up. This is somehow in line with 
the native chronic aortic regurgitation natural history 
studies. The long-term survival of volume overload of 
chronic moderate aortic regurgitation is remarkably good 
and the mortality is associated with symptoms devel-
opment and hinges on the clear documentation of the 
left ventricular remodeling parameters.13 Conversely, the 
studies that showed a higher mortality aortic regurgita-
tion post-TAVR failed to demonstrate aortic regurgitation 
progression over time, left ventricular remodeling or 
worsening of functional class symptoms. 
Nevertheless, independent of whether or not 
the post-TAVR aortic regurgitation is a mediator or 
moderator of poor outcomes, this data underscores 
the actual procedural limitation and the window of 
oppor-tunity to improve the technology. Advances in the 
new TAVR devices are ongoing and include modifica-
tions that will limit effectively or eliminate the aortic 
regurgitation post-TAVR.14 For now the best strategy is 
to adopt preventive measures to reduce the incidence 
of aortic regurgitation such as selecting the adequate 
size and prosthesis for each patient. One important 
developing area is the understanding of aortic-valve 
complex through the multimodality image analysis.15 
These studies focused on the annulus and against the 
prior belief of a simple circular, compliant and static 
structure geometry, the current knowledge about this 
“virtual” ovoid ring is far beyond the possibility of a 
single dimension analysis. Recently, the forth dimension 
was added to the annulus measurement – the time – 
and confirmed the dimension variability according to 
the cardiac cycle phase.16 Herein, the incorporation of 
the multidimensional analysis by means of multidetec-
tor computer tomography and two dimensional/three 
dimensional echocardiogram has proven to be useful.
The advent of TAVR has transformed the aortic ste-
nosis treatment and forced the Interventional Cardiology 
to re-engineering not only our labs but also the way 
in which we interact with the different components 
of a functioning heart-team with the aim of improv-
ing patient prognosis. Whether the aortic regurgitation 
post-TAVR represents a real “fall from grace” or just a 
“storm in a teacup” is still unknown. Further studies 
designed specifically to answer this question are war-
ranted to ensure the TAVR future potential application 
on intermediate and low-risk populations.
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